Sold as Calciparine. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Heparin Calcium (sold as Calciparine), with 0 new uses approved and 0 published complete response letters.
| Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk FeaturesPulmonary Embolism · China National Center for Cardiovascular Diseases | Phase 3 | Not yet recruiting | Nov 4, 2026 |
| Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Nov 4, 2026 |
| Effect of LMWH on Neonatal Outcomes in Isolated OligohydramniosOligohydramnios, Heparin · PAEC General Hospital, Islamabad | Phase 4 | Recruiting | Oct 30, 2026 |
| Danang Cerebral Venous Thrombosis RegistryCerebral Venous Sinus Thrombosis, Stroke · Da Nang Hospital | — | Recruiting | Oct 22, 2026 |
| Post Pulmonary Embolism In Patients Treated With Catheter Based TherapyPulmonary Embolism Acute · Assiut University | Not applicable | Not yet recruiting | Oct 21, 2026 |
| Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyTotal Knee Arthroplasty, Venous Thromboembolism · Military Hospital of Tunis | Not applicable | Recruiting | Oct 9, 2026 |
| Fasciotomy and Predilation for Radial Artery Grafts in CABGCoronary Artery Bypass, Radial Artery Grafts · Ruijin Hospital | Not applicable | Recruiting | Oct 9, 2026 |
| TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring ImmobilizationLower Extremity Injuries, Venous Thromboembolism (VTE) · University of Monastir | — | Recruiting | Oct 7, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| — | CalciparineNDA 18237 | Sanofi Aventis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA